|Mr. Michael J. Valentino||Exec. Chairman||393.75k||N/A||1954|
|Ms. Natasha Giordano||CEO, Pres & Director||884.88k||N/A||1960|
|Ms. Rita M. O'Connor CPA, CPA||CFO and Head of Manufacturing & Supply Chain||623.23k||N/A||1968|
|Mr. Ronald R. Zimmerman||Founder & Sr. Advisor||N/A||N/A||1953|
|Mr. Tom Long||VP of Manufacturing & Technical Operations||N/A||N/A||N/A|
|Ms. Janet M. Barth||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Joanne Cotignola||VP of Marketing||N/A||N/A||N/A|
|Ms. Nicole Godino||National Sales Director||N/A||N/A||N/A|
|Mr. Patrick M. Lonergan||Member of Chief Exec. Officer Advisory Group||N/A||N/A||1935|
|Mr. Charles Edmund Sheedy C.F.A., CFA||Member of Chief Exec. Officer Advisory Group||N/A||N/A||1947|
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
PLx Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.